• Philip B Adamson, William T Abraham, Mark Aaron, Juan M Aranda, Robert C Bourge, Andrew Smith, Lynne W Stevenson, Jordan G Bauman, and Jay S Yadav.
• Heart Failure Institute at Oklahoma Heart Hospital and the Oklahoma Foundation for Cardiovascular Research, Oklahoma City, Oklahoma 73120, USA. padamson@ocaheart.com
• J. Card. Fail. 2011 Jan 1; 17 (1): 3-10.

BackgroundDecompensated heart failure (HF) is associated with unacceptable morbidity and mortality risks. Recent implantable technology advancements allow frequent filling pressure monitoring and provide insight into HF pathophysiology and a new tool for HF management.MethodsThe CHAMPION trial is a prospective, multicenter, randomized, single-blind clinical trial testing the hypothesis that HF management guided by frequently assessed pulmonary artery pressures is superior to traditional methods. A total of 550 subjects with New York Heart Association (NYHA) functional class III HF were enrolled at 64 sites in the United States. All subjects received the CardioMEMS HF sensor as a permanent pulmonary artery implant and were randomized to the treatment or the control group before discharge. The treatment group received traditional HF management guided by hemodynamic information from the sensor. The control group received traditional HF disease management. Safety endpoints include freedom from device/system-related complications and freedom from HF sensor failure at 6 months. The efficacy endpoint is a reduction in the rate of HF-related hospitalizations in the treatment group versus the control group at 6 months.ConclusionsThe CHAMPION trial will investigate the safety and clinical efficacy of the CardioMEMS hemodynamic monitoring system and may establish this management strategy as a new paradigm for the medical management of patients with symptomatic HF.Copyright © 2011 Elsevier Inc. All rights reserved.

20 keywords...

hide…